Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
“Does sermorelin work” is two questions. Does it raise growth hormone and IGF-1? Yes, and the trials are clear on that. Does raising those numbers produce the changes people buy it for, in muscle, fat, sleep, and energy? The trials are smaller, older, and more mixed than any sales page admits. I read the primary literature before we added sermorelin to our program. This is what it says.
What Sermorelin Does Mechanically
Sermorelin is a 29-amino-acid fragment of growth hormone-releasing hormone, the signal the hypothalamus sends to the pituitary. It binds the GHRH receptor on pituitary cells and prompts them to release growth hormone in the body’s normal pulsatile pattern, rather than delivering growth hormone from outside. The 1999 BioDrugs review that summarized its pharmacology from the pediatric approval trials describes it as well tolerated, with injection-site reactions and transient flushing the most common adverse events.[1]
That mechanism is the strongest argument for sermorelin over synthetic HGH: the pituitary’s own feedback stays in control.
The Hormone Response Is Real
A 1992 NIH study gave 10 healthy men aged 68 on average twice-daily GHRH(1-29) for 14 days at two doses. The higher dose raised 24-hour growth hormone and IGF-1 enough that the older men’s levels no longer differed significantly from a comparison group of men in their 20s.[2]
A 1997 trial from UC San Diego went longer. Nineteen adults aged 55 to 71 injected a GHRH analog nightly for 16 weeks after a four-week placebo run-in. Integrated overnight growth hormone rose 107 percent in men and 70 percent in women, and IGF-1 rose 28 percent within two weeks.[3]
So the first question has a firm answer. Sermorelin and its close analogs restore growth hormone and IGF-1 in older adults, in controlled trials, with consistent results.
The Body Composition Results Are Mixed
The same 1997 trial measured what those hormone changes did. Lean body mass increased in men but not in women. Skin thickness increased in both. Insulin sensitivity improved in men only. There were no other changes in body composition or bone density in either sex, and body weight was unchanged.[4]
The authors noted that the anabolic effects favored men, and called for further study of the sex difference. That study, nearly 30 years later, has not been done at scale.
What this means in practice: a man in his 60s can reasonably expect some lean mass gain over four months. A woman may not. Fat loss, which is the outcome most people want, did not appear in the trial at all.
Sleep
This is where the marketing and the data diverge most. Growth hormone is released mainly during deep sleep, which has led to the claim that sermorelin improves sleep. In the 16-week UCSD trial, sleep quality was assessed by questionnaire and was unaffected in both sexes.[4] A separate 1997 study gave GHRH intravenously to 13 adults averaging 69 years old and found fewer nighttime awakenings and a longer first non-REM sleep period, but concluded that the sleep-promoting effect in the elderly was much weaker than in young subjects.[5]
If better sleep is your main reason for considering sermorelin, the evidence is thin.
Well-Being, Immune Markers, and Safety
The UCSD group reported improved general well-being and libido in men but not women,[4] and a companion paper found broad activation of immune cell markers in both sexes over the 16 weeks.[3] The only adverse effect in the longer trial was transient elevation of blood lipids that resolved by the end of the study.[4]
What a Fair Reading Looks Like
Sermorelin works at the level the trials tested: it reliably raises growth hormone and IGF-1 in older adults. The downstream effects are modest, sex-dependent, and best supported for lean mass in men. Fat loss and sleep improvement are not supported by the controlled data. The studies are small, mostly from the 1990s, and no large modern trial exists.
That is a reasonable basis for a provider-supervised program with lab monitoring and realistic goals. It is not a basis for the transformation language that dominates the market. If you want to see how we structure the program around IGF-1 monitoring and dose adjustment, visit our sermorelin therapy page and our article on sermorelin dosing.
References
Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PubMed: 18031173
Corpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. J Clin Endocrinol Metab. 1992;75(2):530-535. PubMed: 1379256
Khorram O, Yeung M, Vu L, Yen SS. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab. 1997;82(11):3590-3596. PubMed: 9360512
Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. PubMed: 9141536
Guldner J, Schier T, Friess E, Colla M, Holsboer F, Steiger A. Reduced efficacy of growth hormone-releasing hormone in modulating sleep endocrine activity in the elderly. Neurobiol Aging. 1997;18(5):491-495. PubMed: 9390775
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized guidance.
JP Rius is the founder of Precision Telemed. His perspective is shaped by the commercial, regulatory, and operational side of telehealth medicine.
